In the short to medium term Vernalis may seem a value buy especially with brokers lining up with "Buy" ratings. The wisdom may be questionable given the share price slumped 20% when poor interim results were announced. There are opportunities for good news: CCP-07 & 08 could both be FDA approved by June 2017 and potential for more milestone payment announcements. June's expected Tuzistra sales update is a potential and serious banana peel. It will also act as an early indication of Final Results due to be announced in September 2017.